Prodrugs of Perzinfotel with Improved Oral Bioavailability
Citations Over TimeTop 18% of 2009 papers
Abstract
Previous studies with perzinfotel (1), a potent, selective, competitive NMDA receptor antagonist, showed it to be efficacious in inflammatory and neuropathic pain models. To increase the low oral bioavailability of 1 (3-5%), prodrug derivatives (3a-h) were synthesized and evaluated. The oxymethylene-spaced diphenyl analogue 3a demonstrated good stability at acidic and neutral pH, as well as in simulated gastric fluid. In rat plasma, 3a was rapidly converted to 1 via 2a. Pharmacokinetic studies indicated that the amount of systemic exposure of 1 produced by a 10 mg/kg oral dose of 3a was 2.5-fold greater than that produced by a 30 mg/kg oral dose of 1. Consistent with these results, 3a was significantly more potent and had a longer duration of activity than 1 following oral administration in a rodent model of inflammatory pain. Taken together, these results demonstrate that an oxymethylene-spaced prodrug approach increased the bioavailability of 1.
Related Papers
- → Oral bioavailability of 17 β-estradiol and prodrugs tested in rats, pigs and dogs(1996)8 cited
- → Synthesis and relative bioavailability of meptazinol benzoyl esters as prodrugs(2005)3 cited
- → Glucose Does Not Reverse Impairments on Spontaneous Alternation Induced by the Noncompetitive NMDA Antagonist MK-801(1995)13 cited
- Prodrug Decision of Novel Genistein Sulfonate and Its Bioavailability in Rats(2012)
- Pre-clinical pharmacokinetics of novel soybean iosflavone sulfonate(2012)